Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Prostate Cancer Screening using Machine Learning

Principal Investigator
Name
Jerry John Rawlings Mensah
Institution
Virginia Commonwealth University
Position Title
Graduate Student
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
PLCO-1732
Initial CDAS Request Approval
Nov 5, 2024
Title
Prostate Cancer Screening using Machine Learning
Summary
Early detection and risk estimation of Prostate Cancer (PCa) is especially important for effective treatment and good clinical outcomes. Early screenings using the serum Prostate-Specific Antigen (PSA) test are usually less invasive and cheaper than other PCa tests which involve biopsies, MRI, or rectal exams – that can be invasive, expensive, or both. Although PSA testing is very common, it is a controversial topic arising from the lack of clear guidelines on serum PSA threshold for diagnoses and treatment, as well as accuracy issues such as sensitivity and specificity that can lead to overdiagnosis or overtreatment. As a result, organizations such as the United States Preventive Services Task Force (USPSTF) recommend against PSA screening for other measures such as shared decision-making between providers and patients, with consideration of individual patient risk factors including age, life expectancy, family history, and race/ ethnicity. This project will use machine learners that will combine the USPSTF measures with PSA, digital rectal exam screening results, and other important baseline clinical and epidemiologic variables to train and evaluate machine learning models to predict prostate cancer risk and incidence over 10-13 years.
Aims

The goal of this study is to explore another equally cheaper and alternative method for first-line Prostate Cancer screening that builds on the advantages of PSA testing and improves upon its limitations.

Collaborators

Dr Emmanuel Taylor - VCU School of Public Health/ Massey Comprehensive Cancer Center